Some of the most representative examples of these ncRNA molecules currently in clinical trials are miR-31 and miR-210 (oral cancer), miR-34a (melanoma, primary liver cancer, multiple myeloma, lymphoma, among other cancers), miR-100 (breast cancer), miR-155 (bladder cancer), miR-16 (non-small cell lung cancer and malignant pleural mesothelioma), miR-221 and miR-222 (hepatocellular carcinoma), THRIL and PACER (stomach cancer), and HOTAIR (thyroid cancer) [199]. This evidence concerns the gene THRIL and non-small cell lung carcinoma.